Mymd Pharmaceuticals (NASDAQ:QCLS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Mymd Pharmaceuticals (NASDAQ:QCLS) from a strong sell rating to a sell rating in a research report report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mymd Pharmaceuticals in a report on Friday, August 7th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Up 2.8%

NASDAQ QCLS opened at $0.78 on Friday. Mymd Pharmaceuticals has a 12 month low of $0.42 and a 12 month high of $8.94. The company has a market capitalization of $6.43 million, a P/E ratio of -0.23 and a beta of 2.09. The firm has a 50-day moving average of $2.43.

Mymd Pharmaceuticals (NASDAQ:QCLS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.79) earnings per share (EPS) for the quarter.

About Mymd Pharmaceuticals

MyMD Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with aging, chronic inflammation and immune-system dysfunction. Its research has centered on small-molecule drug candidates intended to regulate immune and metabolic pathways.

The company’s lead development program has included MYMD-1, an orally administered investigational compound studied for potential applications involving autoimmune disease, chronic inflammation and age-related conditions.